Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with mdscs and tregs in HER2-negative metastatic breast cancer patients
Autor
Papadaki M.A., Aggouraki D., Vetsika E.-K., Xenidis N., Kallergi G., Kotsakis A., Georgoulias V.Datum
2021Language
en
Schlagwort
Zusammenfassung
Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood of patients with metastatic breast cancer (mBC). Materials and Methods: Blood was obtained from 38 pre-treated patients with mBC before a new line of treatment. CTC detection and characterization was performed by triple immunofluorescent staining, while Myeloid-derived Suppressor Cells (MDSCs) and T regulatory cells (Tregs) were analyzed by multi-flow cytometry. Results: CTCs were detected in 16 (42.1%) of patients. Based on the co-expression of ALDH1, TWIST and CK, CTCs revealed an important heterogeneity: CTCs with a CSC/partial-EMT, CSC/Epithelial-like, non-CSC/partial-EMT and non-CSC/Epithelial-like phenotype were detected in 7 (18.4%), 7 (18.4%), 1 (1.4%) and 9 (23.7%) of patients, respectively. Immunophenotyping of MDSCs identified 2 monocytic [M-MDSCs; CD14+CD15+CD11b+CD33+HLADR- Lin- (CD14+CD15+) and CD14+CD15-CD11b+CD33+HLA-DR-Lin- (CD14+CD15-)] and one granulocytic [GMDSCs; CD14-CD15+CD11b+CD33+HLA-DR-Lin- (CD14- CD15+)] subpopulations, expressing inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS), respectively. Patients with detectable CTCs had a higher frequency of Tregs (CD3+CD4+CD25high; p=0.022) whereas a positive correlation was found between CTC counts and the percentage of Tregs (p=0.005) and CD14+CD15+M-MDSCs (p=0.024). Patients with a partial-EMT phenotype had a higher frequency of CD14+CD15+M-MDSCs (p=0.023). Patients harboring the non-CSC/epithelial-like CTC subpopulation had an increased frequency of CD14-CD15+GMDSCs (p=0.020), along with decreased levels of CD3+CD4+CD25high FoxP3+Tregs (p=0.020). Conclusion: These findings provide evidence that CTCs in ER+/HER2- mBC patients may be under the control of the immune system and various immune escape mechanisms might be involved during the different stages of their biological evolution. © 2021 International Institute of Anticancer Research. All rights reserved.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives
Koinis F., Xagara A., Chantzara E., Leontopoulou V., Aidarinis C., Kotsakis A. (2022)Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have ... -
Potential role of immunotherapy for advanced breast cancer
De Mello R.A., Amaral G.A., Tajima C.C., Tadokoro H., Iavelberg J., Simonetti D., Tolia M., Silva J.A. (2021)[No abstract available] -
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes
Kotoula V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., Lakis S., Pentheroudakis G., Bobos M., Papadopoulou K., Tsolaki E., Pectasides D., Lazaridis G., Koutras A., Aravantinos G., Christodoulou C., Papakostas P., Markopoulos C., Zografos G., Papandreou C., Fountzilas G. (2016)The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes ...